Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marathon Digital Holdings Inc (MARA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Marathon Digital Holdings IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Marathon Digital Holdings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Marathon Digital Holdings Inc trades at $9.86 (market cap $3.69B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 22.5× Marathon Digital Holdings Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Marathon Digital Holdings Inc pays none. Which is the better fit depends on your goals.

MARAREGN
Market Cap
$3.69B$83.19B
Sector
TechnologyHealth
52-Week High
$22.84$812.27
52-Week Low
$6.73$555.51
Enterprise Value
$5.74B$77.90B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marathon Digital Holdings Inc

MARA Holdings trades at $10.09, down 5.26% amid a bearish technical signal and recent earnings misses. The stock faces fundamental pressure with a net income margin of -429.71% for 2026 and negative cash flow from operations. Despite this, analyst consensus remains optimistic with a $16.08 price target, and the company is pivoting its power infrastructure toward AI compute to complement Bitcoin mining.

The outlook is mixed; the high analyst buy rating and strategic pivot offer potential upside, but persistent losses, negative cash flow, and Bitcoin market volatility pose significant risks. Investor sentiment is cautious following Q2 2026 results, with the stock trading well below its 52-week high, highlighting both opportunity and substantial downside exposure.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Marathon Digital Holdings Inc

Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.

Read more on MARA

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN